» Articles » PMID: 11168809

Lack of Skin Fibrosis in Tight Skin (TSK) Mice with Targeted Mutation in the Interleukin-4R Alpha and Transforming Growth Factor-beta Genes

Overview
Publisher Elsevier
Specialty Dermatology
Date 2001 Feb 13
PMID 11168809
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Scleroderma is a disorder characterized by fibrosis of the skin and internal organs and autoimmunity. Whereas the cause is unknown, interleukin-4 and transforming growth factor-beta have been postulated to play a major part in the fibrosis. To investigate the part played by these cytokines, we prepared TSK/+ mice with a targeted mutation in the interleukin-4R alpha or transforming growth factor-beta genes. The breeding failed to produce TSK/+ transforming growth factor-beta -/- mice so analysis of the role of transforming growth factor-beta was limited to TSK/+ transforming growth factor-beta +/- mice. We observed that TSK/+ interleukin-4R alpha -/- did not develop dermal thickening, and deletion of one allele of the transforming growth factor-beta gene resulted in diminished dermal thickness compared with TSK/+ mice; however, the deletion of interleukin-4R alpha or transforming growth factor-beta had no effect on lung emphysema, which is another characteristic of TSK syndrome. Electron microscopic analysis of skin showed that the collagen fibrils in TSK/+ interleukin-4R alpha -/- mice exhibit normal periodicity but have a smaller diameter than the fibers found in C57BL/6 mice. Analysis of skin and serum samples showed that the deletion of interleukin-4R alpha or one allele of transforming growth factor-beta prevented the increase of skin thickness paralleled with a decrease in the dermal hydroxyproline content and development of autoantibodies associated with TSK syndrome. These results demonstrate the importance of interleukin-4 and transforming growth factor-beta for the development of cutaneous fibrosis in vivo and suggest an important part for these cytokines in wound healing and connective tissue maintenance in general.

Citing Articles

Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?.

Migayron L, Bordes S, Closs B, Seneschal J, Boniface K Front Immunol. 2024; 15:1405215.

PMID: 38868763 PMC: 11167106. DOI: 10.3389/fimmu.2024.1405215.


STAT6 suppression prevents bleomycin-induced dermal fibrosis.

Huang J, Puente H, Wareing N, Wu M, Mayes M, Karmouty-Quintana H FASEB J. 2023; 37(2):e22761.

PMID: 36629780 PMC: 10226134. DOI: 10.1096/fj.202200994R.


Patients with systemic sclerosis show phenotypic and functional defects in neutrophils.

Impellizzieri D, Egholm C, Valaperti A, Distler O, Boyman O Allergy. 2021; 77(4):1274-1284.

PMID: 34467524 PMC: 9293168. DOI: 10.1111/all.15073.


Defective Early B Cell Tolerance Checkpoints in Patients With Systemic Sclerosis Allow the Production of Self Antigen-Specific Clones.

Glauzy S, Olson B, May C, Parisi D, Massad C, Hansen J Arthritis Rheumatol. 2021; 74(2):307-317.

PMID: 34279059 PMC: 8766600. DOI: 10.1002/art.41927.


New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

Lescoat A, Varga J, Matucci-Cerinic M, Khanna D Expert Opin Investig Drugs. 2021; 30(6):635-652.

PMID: 33909517 PMC: 8292968. DOI: 10.1080/13543784.2021.1923693.